Drug Profile
Research programme: urokinase-type plasmogen activator inhibitors - Pfizer
Alternative Names: UK-371,804Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Guanidines; Sulfonamides
- Mechanism of Action Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Skin ulcer; Wounds
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-ulcer in United Kingdom (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Wounds in United Kingdom (Topical)